MedPath

Teleassisted Surgery for Gynecological Disease in Obese Patients - OB-ALFX

Phase 2
Conditions
Benign, Premalignant and Malignant Gynecological Disease Confined to the Pelvis
Interventions
Device: Telelap ALF-X
Registration Number
NCT02338505
Lead Sponsor
Catholic University of the Sacred Heart
Brief Summary

Phase II prospective single-institutional study.

Detailed Description

The aim of this Phase II prospective single-institutional study is to assess feasibility and early complications rate of Telelap ALF-X surgical treatment in obese patients affected by gynecological disease.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
50
Inclusion Criteria
  • informed consent
  • 30 ≤ BMI < 40
  • ASA < III
  • Ovarian Cyst
  • Prophylactic bilateral salpingo-oophorectomy
  • Ectopic Pregnancy
  • Pelvic Inflammatory Disease
  • Sterility/Infertility
  • Benign uterine disease (fibromatosis, adenomyosis)
  • Endometrial hiperplasia
  • Early-stage Endometrial Cancer
  • Preneoplastic lesions of the cervix
  • IA1 Cervical Cancer
  • Pelvic endometriosis
Exclusion Criteria
  • Pregnancy
  • Liver disease
  • Coagulopathies
  • Clinical conditions contraindicating laparoscopy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Telelap ALF-X in obese patients with gynecological diseaseTelelap ALF-X-
Primary Outcome Measures
NameTimeMethod
intraoperative complication rateintraoperative

Operative time, conversion rate, estimated blood loss, visceral injury

Secondary Outcome Measures
NameTimeMethod
postoperative complication rate30 days

Ileus, bleeding, infection/sepsi, thrombosis, rehospitalization, death

Trial Locations

Locations (1)

Catholic University of Sacred Heart Rome,

🇮🇹

Rome,, Rome, Italy

© Copyright 2025. All Rights Reserved by MedPath